Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
17.32 USD | +4.21% | +4.91% | +1.41% |
May. 01 | Wall Street Set to Open Lower Ahead of Fed Rate Decision; Private Employment Figures Top Forecasts | MT |
May. 01 | Transcript : TG Therapeutics, Inc., Q1 2024 Earnings Call, May 01, 2024 |
Chart calendar TG Therapeutics, Inc.
Upcoming events on TG Therapeutics, Inc.
Past events on TG Therapeutics, Inc.
2024-05-01 08:30 am | Q1 2024 Earnings Call |
2024-05-01 07:00 am | Q1 2024 Earnings Release |
2024-04-17 10:00 am | American Academy of Neurology Meeting - Abstract No: 6023/017 |
2024-04-17 10:00 am | American Academy of Neurology Meeting - Abstract No: 6400/001 |
2024-04-14 07:30 pm | American Academy of Neurology Meeting - Abstract No: 6567/001 |
2024-02-29 06:00 pm | Americas Committee for Treatment and Research in Multiple Sclerosis Forum - Abstract Number: 731 |
2024-02-29 06:00 pm | Americas Committee for Treatment and Research in Multiple Sclerosis Forum - Abstract Number: 720 |
2024-02-28 08:30 am | Q4 2023 Earnings Call |
2024-02-28 07:00 am | Q4 2023 Earnings Release |
2024-01-09 07:30 pm | JPMorgan Healthcare Conference |
2023-11-29 02:10 pm | Evercore ISI HealthCONx Conference - Fireside Chat |
2023-11-06 03:10 pm | Guggenheim Securities Inflammation & Immunology Conference |
2023-11-01 08:30 am | Q3 2023 Earnings Call |
2023-11-01 07:30 am | Q3 2023 Earnings Release |
2023-10-12 11:00 am | European Committee for Treatment and Research in Multiple Sclerosis Meeting - Poster No: P641 |
2023-10-11 10:30 am | European Committee for Treatment and Research in Multiple Sclerosis Meeting - Poster No: P162 |
2023-10-11 02:00 am | European Committee for Treatment and Research in Multiple Sclerosis Meeting - Poster No: P1683 |
2023-09-26 12:25 pm | Cantor Global Healthcare Conference - Fireside Chat |
2023-09-11 10:30 am | H.C. Wainwright Global Investment Conference |
2023-08-01 08:30 am | Q2 2023 Earnings Call |
Annual results
Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|
Net sales Million USD | Released Forecast Spread | 0,15 0,17 -11.63% | 0,15 0,17 -9.52% | 6,69 6,97 -4% | 2,79 4,27 -34.74% | 234 231 1.12% | 309 |
EBITDA Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | -344 -352 2.07% | -193 -173 -11.02% | 20,8 20,6 1.24% | 29,2 |
EBIT Million USD | Released Forecast Spread | -169 -172 1.67% | -274 -258 -6% | -345 -337 -2.3% | -193 -177 -8.89% | 20,6 18,7 10.47% | 3,88 |
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -173 -168 -2.97% | -279 -260 -7.62% | -348 -339 -2.62% | -198 -185 -7.23% | 13,1 10,4 26.19% | -10,7 |
Net income Million USD | Released Forecast Spread | -173 -173 0.2% | -279 -263 -6.12% | -348 -339 -2.61% | -198 -182 -9.06% | 12,7 11,6 8.8% | -3,31 |
EPS USD | Released Forecast Spread | -1,96 -1,97 0.51% | -2,42 -2,28 -6.01% | -2,63 -2,55 -3.15% | -1,46 -1,39 -5.42% | 0,09 0,08 12.82% | -0,02 |
Announcement Date | 02/03/20 | 01/03/21 | 01/03/22 | 28/02/23 | 28/02/24 | - |
Quarterly results
Fiscal Period | December | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales Million USD | Released Forecast Spread | 2,02 2,08 -2.86% | 0,59 0,18 238.6% | 0,09 1,70 -94.47% | 0,08 1,60 -95.01% | 7,80 3,38 130.93% | 16,1 17,9 -10.43% | 166 63,3 161.8% | 44,0 40,1 9.75% | 63,5 54,6 16.24% | 65,9 | 78,0 | 89,7 | 88,6 | 116 |
EBITDA Million USD | Released Forecast Spread | -66,8 -92,0 27.4% | -38,9 -77,0 49.53% | -52,0 -42,0 -23.78% | -36,9 -52,0 28.99% | -44,6 -35,0 -27.55% | 115 97,0 18.41% | -12,4 -17,0 26.78% | -9,24 0,00 - | -3,00 | 5,00 | 13,0 | |||
EBIT Million USD | Released Forecast Spread | -66,9 -82,3 18.73% | -38,9 -72,7 46.45% | -35,0 -46,6 24.94% | -52,1 -36,5 -42.7% | -37,0 -50,2 26.31% | -44,7 -33,6 -32.92% | 115 4,26 2593.01% | -12,5 -15,5 19.62% | -9,27 -6,12 -51.48% | -5,13 | 0,53 | 7,77 | 10,4 | 39,3 |
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -69,0 -80,0 13.71% | -40,5 -61,7 34.29% | -35,8 -41,5 13.67% | -53,0 -39,7 -33.59% | -39,2 -52,3 25% | -47,6 -35,0 -35.99% | 114 45,8 148.9% | -14,0 -16,7 16.07% | -10,7 -4,27 -150.07% | -7,09 | -0,36 | 5,99 | 18,9 | 36,3 |
Net income Million USD | Released Forecast Spread | -69,0 -80,0 13.71% | -40,5 -66,4 38.96% | -35,8 -46,3 22.69% | -53,0 -36,6 -44.9% | -39,2 -52,3 25% | -47,6 -36,5 -30.48% | 114 51,1 122.83% | -14,4 -16,7 13.74% | -10,7 -6,39 -67.51% | -7,09 | -2,47 | 5,73 | 18,2 | 33,8 |
EPS USD | Released Forecast Spread | -0,51 -0,57 11.01% | -0,30 -0,47 36.33% | -0,26 -0,33 21.37% | -0,39 -0,25 -53.37% | -0,28 -0,35 19.42% | -0,34 -0,25 -33.71% | 0,73 0,17 329.41% | -0,10 -0,11 11.46% | -0,07 -0,04 -61.55% | -0,05 | -0,02 | 0,04 | 0,12 | 0,21 |
Announcement Date | 10/05/22 | 08/08/22 | 09/11/22 | 28/02/23 | 01/05/23 | 01/08/23 | 01/11/23 | 28/02/24 | 01/05/24 | - | - | - | - | - |
2024-05-13 | BELITE BIO, INC: Q1 2024 Earnings Release |
2024-05-13 | POLARIS GROUP: Q1 2024 Earnings Release |
2024-05-13 | ABSCI CORPORATION: Q1 2024 Earnings Release |
2024-05-14 | GNI GROUP LTD.: Q1 2024 Earnings Release |
2024-05-15 | REPLIMUNE GROUP, INC.: Q4 2024 Earnings Release (Projected) |
2024-05-17 02:00 am | BIOARCTIC AB: Q1 2024 Earnings Release |
2024-05-20 | ALVOTECH: Q1 2024 Earnings Release |
2024-05-21 | CUREVAC N.V.: Q1 2024 Earnings Release (Projected) |
2024-05-21 | EXSCIENTIA PLC: Q1 2024 Earnings Release (Projected) |
2024-05-21 | EVOTEC SE: Q1 2024 Earnings Release |
Past sector events for TG Therapeutics, Inc.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- TGTX Stock
- Calendar TG Therapeutics, Inc.